전립선 암종의 신생혈관 형성과 세포 증식능 및 전립선특이항원 발현정도가 종양전이 및 예후에 미치는 영향 = Predictors of Metastasis and Prognosis in Prostate Carcinoma : The Role of Neovascularity, Proliferating Cell Nuclear Antigen and Prostate Specific Antigen Expression
Prostate adenocarcinoma is a significant cause of morbidity and mortality in old men. Recently, with increased screening, there has been much interest in early detection and proper management of this cancer. The best predictors of prognosis in prostate cancer are the stage of disease and histologic differentiation of the cancer. But, preoperative prediction of pathologic stage in prostate cancer is currently limited and histologic differentiation may be somewhat subjective. Therefore, more accurate predictors of biological progression are needed. A number of markers including DNA ploidy, prostate specific antigen(PSA) level, oncogenes, tumor suppressor genes and expression of proteins related to proliferation have been suggested to aid the stage and histologic differentiation in predicting the malignant potential of prostate cancers.
The authors designed this study to determine the prediction efficacies of neovascularity, proliferating cell nuclear antigen(PCNA) labeling index and intensity of PSA reaction using immunohistochemical staining, To evaluated above mentioned 3 markers, immunohistochemical stains in 48 cases of prostate cancers and 5 cases of benign prostatic hyperplasia(BPH) were performed and analysed. Microvessels were identified by immunostaining of endothelial cells for factor Ⅷ-related antigen. PCNA labeling indices were obtained in 200X field by counting more than 1,000 cells. The intensity of PSA staining was graded as 0, 1, 2, 3, based on its relationship to the control, and used as scores. The most outstanding staining was considered as 3.
The results were as follows:
1. The mean microvessel count(MVC) in BPH group was 34.2±5.9 per 200X field and that of prostate cancer group was 63.5±38.6(p〈0.05). The mean MVC of Gleason grade I prostate cancer was 32.2(16-40). The MVCs were 38.3(23-58), 58.8(23-92), 78.1(18-182) and 86.8(22-180), from grade Ⅱ to V respectively. According to stage, the mean MVCs were 40.8, 48.5, 55.0 and 89.0 from A to D. Between the 2 groups with well differentiated(grade I-Ⅲ) and poorly differentiated(grade Ⅳ-Ⅴ) prostate cancer, there was significant difference in MVC(p〈0.05). And between localized and metastatic group, there was also significant difference. The mean survival of high MVC(MVC≥60) group was 57.4±15.9 months and that of low MVC group was 74.0±11.2 months. But the difference was not statistically significant.
2. The mean PCNA labeling indices were 14.6±8.0% in BPH group and 32.3±15.4% in prostate cancer group. According to Gleason grade, the mean PCNA labeling indices showed the distribution of 33.4(11-55)%, 30.8(19-41)%, 26.3(8-74)%, 38.0(22-55)% and 36.6(12-72)% from I to V respectively. According to stage, the mean value of stage A was 23.1(11-55)%. The mean values were 27.4(8-41)%, 30.4(21-51%) and 36.2(8-74)% in stage B, C and D. Between localized and metastatic group, the difference of PCNA labeling index was not statistically significant. The mean survival of high labeling index(≥30%) group was 66.0±12.2 months contrasted with 72.4±14.6 months of low labeling index group(p〉0.05).
3. The intensities of PSA staining were as follows: according to grade, from I to V, they were 2, 20, 2.75, 2.50, 1.73 and 1.20, respectively. In stage A, the mean PSA score was 2.67, and those of other stages were 2.62 in B, 2.60 in C and 1.58 in D. Between the 2 groups with well differentiated and poorly differentiated prostate cancer, there was significant differnce in PSA score(p〈0.05). And between localized and metastatic group, there was also significant difference. The mean survival of high intensity(2, 3) group was 74.1±11.6 months contrasted with 48.9±11.5 months in low intensity group(0, 1). But the difference was not statistically significant.
These results suggest that microvessel density in prostate adenocarcinoma may be an another prognostic factor supporting clinical stage and histologic differentiation. In addition, the intensity of PSA immunostaining can be used as a predictor of malignant potential. But relatively negative results were obtained for PCNA labeling index from this study. To further define MVC and PSA staining intensity as predictors of prostate cancer, more enthusiastic and well designed studies are needed.
서지정보 내보내기(Export)
닫기소장기관 정보
닫기권호소장정보
닫기오류접수
닫기오류 접수 확인
닫기음성서비스 신청
닫기음성서비스 신청 확인
닫기이용약관
닫기학술연구정보서비스 이용약관 (2017년 1월 1일 ~ 현재 적용)
학술연구정보서비스(이하 RISS)는 정보주체의 자유와 권리 보호를 위해 「개인정보 보호법」 및 관계 법령이 정한 바를 준수하여, 적법하게 개인정보를 처리하고 안전하게 관리하고 있습니다. 이에 「개인정보 보호법」 제30조에 따라 정보주체에게 개인정보 처리에 관한 절차 및 기준을 안내하고, 이와 관련한 고충을 신속하고 원활하게 처리할 수 있도록 하기 위하여 다음과 같이 개인정보 처리방침을 수립·공개합니다.
주요 개인정보 처리 표시(라벨링)
목 차
3년
또는 회원탈퇴시까지5년
(「전자상거래 등에서의 소비자보호에 관한3년
(「전자상거래 등에서의 소비자보호에 관한2년
이상(개인정보보호위원회 : 개인정보의 안전성 확보조치 기준)개인정보파일의 명칭 | 운영근거 / 처리목적 | 개인정보파일에 기록되는 개인정보의 항목 | 보유기간 | |
---|---|---|---|---|
학술연구정보서비스 이용자 가입정보 파일 | 한국교육학술정보원법 | 필수 | ID, 비밀번호, 성명, 생년월일, 신분(직업구분), 이메일, 소속분야, 웹진메일 수신동의 여부 | 3년 또는 탈퇴시 |
선택 | 소속기관명, 소속도서관명, 학과/부서명, 학번/직원번호, 휴대전화, 주소 |
구분 | 담당자 | 연락처 |
---|---|---|
KERIS 개인정보 보호책임자 | 정보보호본부 김태우 | - 이메일 : lsy@keris.or.kr - 전화번호 : 053-714-0439 - 팩스번호 : 053-714-0195 |
KERIS 개인정보 보호담당자 | 개인정보보호부 이상엽 | |
RISS 개인정보 보호책임자 | 대학학술본부 장금연 | - 이메일 : giltizen@keris.or.kr - 전화번호 : 053-714-0149 - 팩스번호 : 053-714-0194 |
RISS 개인정보 보호담당자 | 학술진흥부 길원진 |
자동로그아웃 안내
닫기인증오류 안내
닫기귀하께서는 휴면계정 전환 후 1년동안 회원정보 수집 및 이용에 대한
재동의를 하지 않으신 관계로 개인정보가 삭제되었습니다.
(참조 : RISS 이용약관 및 개인정보처리방침)
신규회원으로 가입하여 이용 부탁 드리며, 추가 문의는 고객센터로 연락 바랍니다.
- 기존 아이디 재사용 불가
휴면계정 안내
RISS는 [표준개인정보 보호지침]에 따라 2년을 주기로 개인정보 수집·이용에 관하여 (재)동의를 받고 있으며, (재)동의를 하지 않을 경우, 휴면계정으로 전환됩니다.
(※ 휴면계정은 원문이용 및 복사/대출 서비스를 이용할 수 없습니다.)
휴면계정으로 전환된 후 1년간 회원정보 수집·이용에 대한 재동의를 하지 않을 경우, RISS에서 자동탈퇴 및 개인정보가 삭제처리 됩니다.
고객센터 1599-3122
ARS번호+1번(회원가입 및 정보수정)